Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 5/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497184 | 0.87 | THRB (0.39) | PTGS1PTGS2OPRK1HTTKMT2A | |
| SCHEMBL17339212 | 0.87 | THRB (0.39) | PTGS1PTGS2OPRK1HTTKMT2A | |
| SCHEMBL24866320 | 0.87 | THRB (0.39) | PTGS1PTGS2OPRK1HTTKMT2A | |
| SCHEMBL24866551 | 0.87 | THRB (0.39) | PTGS1PTGS2OPRK1HTTKMT2A | |
| SCHEMBL497183 | 0.83 | HTT (0.39) | PTGS1PTGS2OPRK1HTTKMT2A | |
| SCHEMBL9731960 | 0.83 | HTT (0.39) | PTGS1PTGS2OPRK1HTTKMT2A | |
| SCHEMBL16592885 | 0.82 | ALDH1A1 (0.33) | PTGS1PTGS2OPRK1HTTKMT2A | |
| SCHEMBL16592841 | 0.82 | ALDH1A1 (0.33) | PTGS1PTGS2OPRK1HTTKMT2A | |
| SCHEMBL16602948 | 0.82 | PTGS2 (0.42) | PTGS1PTGS2OPRK1HTTKMT2A | |
| SCHEMBL16602949 | 0.82 | PTGS2 (0.42) | PTGS1PTGS2OPRK1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598479-B1 | A METHOD FOR PREPARING RAMIPRIL | AARTI HEALTHCARE LTD (IN) | 2015-04-01 | — | — | EP | disclosed |
| US-8263784-B2 | Method for the synthesis of a ramipril intermediate | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2012-09-11 | — | — | US | disclosed |
| US-8263784-B2 | Method for the synthesis of a ramipril intermediate | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2012-09-11 | — | — | US | disclosed |
| US-8263784-B2 | Method for the synthesis of a ramipril intermediate | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2012-09-11 | — | — | US | disclosed |
| WO-2012063252-A2 | A METHOD FOR PREPARING RAMIPRIL | AARTI HEALTHCARE LIMITED (IN) | 2012-05-18 | — | — | WO | disclosed |
| US-8105807-B2 | Carbamoylglycine derivatives | DSM IP ASSETS B.V. (NL) | 2012-01-31 | — | — | US | disclosed |
| EP-2200981-B1 | NOVEL CARBAMOYLGLYCINE DERIVATIVES | DSM IP ASSETS BV (NL) | 2011-12-07 | — | — | EP | disclosed |
| EP-2200981-B1 | NOVEL CARBAMOYLGLYCINE DERIVATIVES | DSM IP ASSETS BV (NL) | 2011-12-07 | — | — | EP | disclosed |
| US-20110263871-A1 | METHOD FOR THE SYNTHESIS OF A RAMIPRIL INTERMEDIATE | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2011-10-27 | — | — | US | disclosed |
| US-20110263871-A1 | METHOD FOR THE SYNTHESIS OF A RAMIPRIL INTERMEDIATE | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2011-10-27 | — | — | US | disclosed |
| US-20110263871-A1 | METHOD FOR THE SYNTHESIS OF A RAMIPRIL INTERMEDIATE | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2011-10-27 | — | — | US | disclosed |
| EP-2344455-A1 | METHOD FOR THE SYNTHESIS OF A RAMIPRIL INTERMEDIATE | DSM IP Assets B.V. (NL) | 2011-07-20 | — | — | EP | disclosed |
| US-20100221796-A1 | NOVEL CARBAMOYLGLYCINE DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2010-09-02 | — | — | US | disclosed |
| US-20100221796-A1 | NOVEL CARBAMOYLGLYCINE DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2010-09-02 | — | — | US | disclosed |
| US-20100221796-A1 | NOVEL CARBAMOYLGLYCINE DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2010-09-02 | — | — | US | disclosed |
| EP-2200981-A1 | NOVEL CARBAMOYLGLYCINE DERIVATIVES | DSM IP Assets B.V. (NL) | 2010-06-30 | — | — | EP | disclosed |
| WO-2010049401-A1 | METHOD FOR THE SYNTHESIS OF A RAMIPRIL INTERMEDIATE | DSM IP ASSETS B.V. (NL) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010049401-A1 | METHOD FOR THE SYNTHESIS OF A RAMIPRIL INTERMEDIATE | DSM IP ASSETS B.V. (NL) | 2010-05-06 | — | — | WO | disclosed |
| WO-2009050041-A1 | NOVEL CARBAMOYLGLYCINE DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009050041-A1 | NOVEL CARBAMOYLGLYCINE DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100221796-A1 | NOVEL CARBAMOYLGLYCINE DERIVATIVES | DNPEP, ACE, PEPD | PTGS1 449/4885PTGS2 819/4885OPRK1 488/4885 |
| US-20110263871-A1 | METHOD FOR THE SYNTHESIS OF A RAMIPRIL INTERMEDIATE | POR, CYP11B2, CYP1A2 | PTGS1 169/4885PTGS2 184/4885OPRK1 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.